Insights
Media Center
Latest Therapy Updates
- Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
- World’s First Solid-Tumor CAR-T Product Advances in Clinical Use: First International Patient Completes Cell Collection at Jiahui International Cancer Center
- Orpathys® approved in China to treat gastric cancer patients with MET amplification
- Sichuan Biokin Pharmaceutical Co., Ltd. voluntarily disclosed the announcement about the approval of izalontamab brengitecan (BL-B01D1/iza-bren)
- Announcement of Jiangsu Hengrui Pharmaceutical Co., Ltd. on Obtaining Drug Registration Approval
Page 4 of 12
What could this mean for your care?
A promising treatment raises a personal question: could it be an option for you? Chirona helps you explore that question with the right specialists.
Start a case reviewHow our service worksUnderstand your options
Explore the treatments relevant to your diagnosis, previous care and priorities.
Bring your case to specialists
We help organise your medical records and coordinate a professional assessment of suitability and access.
Plan the next step together
If a treatment path is appropriate, we help coordinate consultations, hospital arrangements and continuity of care.